ESH CLL 2022 | Selecting CLL patients for CAR-T therapy
Marco Ruella
• 14 Mar 2022
Marco Ruella, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses the selection of chronic lymphocytic leukemia (CLL) patients for chimeric antigen receptor T-cell (CAR-T) therapy. Dr Ruella explains that patients who will likely benefit the most from CAR-T clinical trials are those that are younger and have high-risk disease, as they are less likely to respond to small molecule inhibition in the long-term. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
